相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Christophe Schmitt et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
Michael U. Callaghan et al.
BLOOD (2021)
Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data
Mudi Misgav et al.
HAEMOPHILIA (2021)
Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
Patrick T. Ebbert et al.
HAEMOPHILIA (2020)
Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres
John Michael Soucie et al.
HAEMOPHILIA (2020)
Emicizumab treatment and monitoring in a paediatric cohort: real-world data
Assaf A. Barg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort
Assaf A. Barg et al.
PEDIATRIC BLOOD & CANCER (2019)
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Steven W. Pipe et al.
LANCET HAEMATOLOGY (2019)
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
Midori Shima et al.
HAEMOPHILIA (2019)
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Guy Young et al.
BLOOD (2019)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The relationship between target joints and direct resource use in severe haemophilia
Jamie O'Hara et al.
HEALTH ECONOMICS REVIEW (2018)
Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia
J. Hanley et al.
HAEMOPHILIA (2017)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Peter J. Lenting et al.
BLOOD (2017)
Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project
Marilyn J. Manco-Johnson et al.
BLOOD (2017)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Midori Shima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Advances and challenges in hemophilic arthropathy
Tine Wyseure et al.
SEMINARS IN HEMATOLOGY (2016)
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
A. Gringeri et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
分享论文
